Cyclerion Therapeutics, Inc.

Equities

CYCN

US23255M2044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-24 pm EDT			5-day change	1st Jan Change
2.77 ^USD	-9.18%		-13.93%	-17.31%

Mar. 05	Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Cyclerion Therapeutics, Inc. Appoints Regina Graul as President	CI

CYCLERION THERAPEUTICS, INC. : Other Events (form 8-K)

October 01, 2020 at 07:23 am EDT

Item 8.01 Other Events

On October 1, 2020, Cyclerion Therapeutics, Inc. provided an update on the timing of disclosing top line results of two clinical trials: olinciguat Phase 2 STRONG study in sickle cell disease patients, and IW-6463 translational pharmacology study, conducted in elderly healthy subjects, to support further development in serious central nervous system (CNS) diseases. As a result of some recent COVID-19 related operational delays in obtaining certain study data, Cyclerion continues to perform analyses of data from both studies, and expects to communicate top line results from both these studies in the coming weeks.

Latest news about Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Cyclerion Therapeutics, Inc. Appoints Regina Graul as President	Dec. 04	CI
Cyclerion Therapeutics, Inc. Announces Board of Directors Appointments	Nov. 30	CI
Cyclerion Therapeutics, Inc. Announces Resignation of Ole Isacson as Director	Nov. 24	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer	23-10-23	CI
Cyclerion Therapeutics Acquires 10% Stake in Tisento Therapeutics in Asset Purchase Deal	23-07-31	MT
Tisento Therapeutics, Inc. announced that it has received $81 million in funding from Cyclerion Therapeutics, Inc., Invus, Polaris, and other investors	23-07-30	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-28	CI
Cyclerion Therapeutics, Inc. Announces Resignation of Cheryl Gault as Chief Operating Officer	23-06-27	CI
Cyclerion Therapeutics, Inc. announced that it has received $5.000001 million in funding	23-05-24	CI
Cyclerion Therapeutics to Implement 1-for-20 Reverse Stock Split	23-05-15	MT
Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Cyclerion Therapeutics to Sell Zagociguat, CY3018 Assets to New Private Company	23-05-12	MT
J & W Cycles, Inc. signed a definitive agreement to acquire sGC Stimulator Assets of Cyclerion Therapeutics, Inc. for $8 million.	23-05-10	CI
Cyclerion in Talks on Buyout Proposal for Drug Assets; CEO Offers to Make Equity Investment	23-04-03	MT
Cyclerion Therapeutics, Inc. announced that it expects to receive $5.000001 million in funding	23-03-30	CI
Cyclerion Therapeutics Says FDA Grants Orphan Drug Designation to Zagociguat; Shares Jump	23-03-27	MT
Cyclerion Gets FDA Orphan Designation for Zagociguat in Mitochondrial Diseases	23-03-27	DJ
Cyclerion Therapeutics' Zagociguat Gets FDA Orphan Drug Status	23-03-23	MT
Cyclerion Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-03-21	CI
North American Morning Briefing : Futures Deep in -3-	23-03-15	DJ
A group including Cyclerion Therapeutics, Inc.'s Chief Executive Officer cancelled the acquisition of Certain Assets of Cyclerion Therapeutics, Inc..	22-11-21	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
Cyclerion Therapeutics, Inc. Announces Resignation of Andreas Busch as Chief Scientific Officer	22-09-30	CI

Chart Cyclerion Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Companyâs portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The Company operates through the human therapeutics segment. The Company is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The Company is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.

Sector

Biotechnology & Medical Research

Calendar

2024-04-30 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
CYCLERION THERAPEUTICS, INC.	-17.31%	7.03M
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+47.81%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research